Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has been assigned a consensus rating of “Hold” from the eight ratings firms that are currently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $8.33.
Several equities analysts have recently issued reports on DRNA shares. ValuEngine cut Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Zacks Investment Research cut Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, August 22nd. HC Wainwright reissued a “buy” rating and set a $5.00 target price on shares of Dicerna Pharmaceuticals in a research note on Tuesday, May 23rd. Finally, Chardan Capital reissued a “hold” rating on shares of Dicerna Pharmaceuticals in a research note on Monday, August 14th.
Several institutional investors and hedge funds have recently bought and sold shares of the company. EcoR1 Capital LLC increased its stake in shares of Dicerna Pharmaceuticals by 101.0% during the second quarter. EcoR1 Capital LLC now owns 767,992 shares of the biopharmaceutical company’s stock valued at $2,435,000 after buying an additional 385,992 shares during the period. Palo Alto Investors LLC increased its stake in shares of Dicerna Pharmaceuticals by 4.0% during the second quarter. Palo Alto Investors LLC now owns 500,913 shares of the biopharmaceutical company’s stock valued at $1,588,000 after buying an additional 19,394 shares during the period. Renaissance Technologies LLC increased its stake in shares of Dicerna Pharmaceuticals by 2.4% during the first quarter. Renaissance Technologies LLC now owns 418,500 shares of the biopharmaceutical company’s stock valued at $1,423,000 after buying an additional 9,818 shares during the period. Vanguard Group Inc. increased its stake in shares of Dicerna Pharmaceuticals by 4.5% during the second quarter. Vanguard Group Inc. now owns 340,327 shares of the biopharmaceutical company’s stock valued at $1,078,000 after buying an additional 14,517 shares during the period. Finally, UBS Group AG increased its stake in shares of Dicerna Pharmaceuticals by 0.6% during the first quarter. UBS Group AG now owns 284,645 shares of the biopharmaceutical company’s stock valued at $968,000 after buying an additional 1,599 shares during the period. 55.54% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Dicerna Pharmaceuticals (DRNA) traded up 2.54% during mid-day trading on Friday, hitting $3.63. 118,646 shares of the stock traded hands. Dicerna Pharmaceuticals has a 52 week low of $2.42 and a 52 week high of $6.10. The stock’s market cap is $75.66 million. The firm’s 50-day moving average is $3.42 and its 200-day moving average is $3.19.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last announced its quarterly earnings data on Thursday, August 10th. The biopharmaceutical company reported ($1.15) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.61) by ($0.54). Dicerna Pharmaceuticals had a negative net margin of 8,474.12% and a negative return on equity of 168.65%. The company had revenue of $0.25 million during the quarter, compared to the consensus estimate of $0.08 million. During the same quarter in the previous year, the firm posted ($0.75) EPS. The business’s revenue for the quarter was up 2400.0% compared to the same quarter last year. On average, analysts forecast that Dicerna Pharmaceuticals will post ($2.70) earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “Dicerna Pharmaceuticals, Inc. (DRNA) Receives $8.33 Average Target Price from Brokerages” was originally reported by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this article on another publication, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The legal version of this article can be viewed at https://sportsperspectives.com/2017/09/12/dicerna-pharmaceuticals-inc-drna-receives-8-33-average-target-price-from-brokerages.html.
About Dicerna Pharmaceuticals
Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
Receive News & Ratings for Dicerna Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.